CD229/SLAMF3 Protein, Human (HEK293, His-Avi)

The CD229/SLAMF3 protein is an autoligand receptor in the SLAM family that regulates immune cell activation and differentiation through cell interactions. Essential for innate and adaptive immune responses, its activity is controlled by SH2D1A/SAP and/or SH2D1B/EAT-2. CD229/SLAMF3 Protein, Human (HEK293, His-Avi) is the recombinant human-derived CD229/SLAMF3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CD229/SLAMF3 Protein, Human (HEK293, His-Avi) is 407 a.a., with molecular weight of 70-80 kDa.

CD229/SLAMF3 Protein is a self-ligand receptor that belongs to the signaling lymphocytic activation molecule (SLAM) family. It functions as a modulator of immune cell activation and differentiation through homo- or heterotypic cell-cell interactions. This receptor plays a crucial role in regulating both innate and adaptive immune responses. The presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2, controls its activities. CD229/SLAMF3 is involved in adhesion reactions between T lymphocytes and accessory cells through homophilic interactions. It promotes the differentiation of T-cells into a helper T-cell Th17 phenotype, leading to increased secretion of IL-17, with the costimulatory activity requiring SH2D1A. Furthermore, it facilitates the recruitment of RORC to the IL-17 promoter. CD229/SLAMF3 may also function as a negative regulator of the immune response, contributing to the maintenance of peripheral cell tolerance. It can inhibit autoantibody responses and IFN-gamma secretion by CD4(+) T-cells. Additionally, it is involved in regulating the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells. CD229/SLAMF3 interacts with SH2D1A, SH2D1B, INPP5D, and PTPN11, with the interaction with PTPN11 being blocked by SH2D1A.

Human

HEK293

C-Avi;C-His

Q9HBG7 (K48-K454)

4063  [NCBI]

70-80 kDa

Greater than 95% as determined by Tris-Bis PAGE.

<1 EU/μg, determined by LAL method.